碩貝德(300322.SZ)2021年度淨利潤預增66.81%-83.5%
格隆匯1月26日丨碩貝德(300322.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤5000萬元-5500萬元,同比增長66.81%-83.50%;扣除非經常性損益後的淨利潤3500萬元-4000萬元,同比增長108.57%-138.36%。業績變動原因如下:
1、報吿期內,公司天線、散熱業務收入保持持續增長,淨利潤保持穩步增長;指紋模組業務受客户端芯片短缺等影響,銷售收入較上年同期下滑。公司通過降本增效、強化管理,提升經營效率,實現業績同比較大增長。
2、報吿期內,非經常性損益對公司淨利潤的影響金額約人民幣1500萬元,主要為參股公司的公允價值變動損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.